» Articles » PMID: 37351737

Impact of Adolescent Nicotine Exposure in Pre- and Post-natal Oxycodone Exposed Offspring

Overview
Date 2023 Jun 23
PMID 37351737
Authors
Affiliations
Soon will be listed here.
Abstract

Perinatal exposure to prescription opioids pose a critical public health risk. Notably, research has found significant neurodevelopmental and behavioral deficits between in utero (IUO) and postnatal (PNO) oxycodone-exposed offspring but there is a notable gap in knowledge regarding the interaction of these groups to other drug exposure, particularly nicotine exposure. Nicotine's widespread use represents a ubiquitous clinical interaction that current research does not address. Children often experiment with drugs and risky behavior; therefore, adolescence is a key timepoint to characterize. This study employed an integrated systems approach to investigate escalating nicotine exposure in adolescence and subsequent nicotine withdrawal in the IUO- and PNO-offspring. Western blot analysis found synaptic protein alterations, especially upregulation of synaptophysin in IUO-withdrawal animals. RT-qPCR further validated immune dysfunction in the central nervous system (CNS). Peripheral nicotine metabolism was consistent with increased catabolism of nicotine concerning IUO animals. Lastly, behavioral assays found subtle deficits to withdrawal in nociception and anxiety-like behavior. This study showed, for the first time, the vulnerabilities of PNO- and IUO-exposed groups concerning nicotine use during early adolescence and withdrawal. Graphical Abstract.

Citing Articles

Neurobehavioral Characterization of Perinatal Oxycodone-Exposed Offspring in Early Adolescence.

Flores A, Nguyen N, Devanaboyina M, Sanketh S, Athota P, Jagadesan S J Neuroimmune Pharmacol. 2024; 19(1):29.

PMID: 38874861 DOI: 10.1007/s11481-024-10129-7.


Advances in animal models of prenatal opioid exposure.

Ferrante J, Blendy J Trends Neurosci. 2024; 47(5):367-382.

PMID: 38614891 PMC: 11096018. DOI: 10.1016/j.tins.2024.03.005.


Developmental outcomes with perinatal exposure (DOPE) to prescription opioids.

Flores A, Nguyen N, Pendyala G NeuroImmune Pharm Ther. 2023; 2(4):339-351.

PMID: 38058996 PMC: 10696573. DOI: 10.1515/nipt-2023-0017.

References
1.
Alburges M, Hoonakker A, Hanson G . Nicotinic and dopamine D2 receptors mediate nicotine-induced changes in ventral tegmental area neurotensin system. Eur J Pharmacol. 2007; 573(1-3):124-32. PMC: 2707996. DOI: 10.1016/j.ejphar.2007.06.063. View

2.
Alipio J, Riggs L, Plank M, Keller A . Environmental Enrichment Mitigates the Long-Lasting Sequelae of Perinatal Fentanyl Exposure in Mice. J Neurosci. 2022; 42(17):3557-3569. PMC: 9053848. DOI: 10.1523/JNEUROSCI.2083-21.2022. View

3.
Ande A, Earla R, Jin M, Silverstein P, Mitra A, Kumar A . An LC-MS/MS method for concurrent determination of nicotine metabolites and the role of CYP2A6 in nicotine metabolite-mediated oxidative stress in SVGA astrocytes. Drug Alcohol Depend. 2012; 125(1-2):49-59. PMC: 3413753. DOI: 10.1016/j.drugalcdep.2012.03.015. View

4.
Babb M, Koren G, Einarson A . Treating pain during pregnancy. Can Fam Physician. 2010; 56(1):25, 27. PMC: 2809170. View

5.
Bruijnzeel A . Neuropeptide systems and new treatments for nicotine addiction. Psychopharmacology (Berl). 2016; 234(9-10):1419-1437. PMC: 5420481. DOI: 10.1007/s00213-016-4513-5. View